Sanders, Rogier W

Publications

Sort by

Co-Author Network

selected publications

HIV-1 envelope trimer vaccine induces sex-associated differences in antibody responses: a phase 1 clinical trial. Nature communications. 2025 Academic Article GET IT
Spike conformational and glycan heterogeneity associated with furin cleavage causes incomplete neutralization of SARS-CoV-2. Nature communications. 2025 Academic Article GET IT
Induction of HIV-1-specific antibody-mediated effector functions by native-like envelope trimers in humans. PLoS pathogens. 2025 Academic Article GET IT
Differential contributions of human oligosaccharyltransferase complexes OST-A and OST-B to HIV-1 envelope glycoprotein glycosylation. 2025 GET IT
A modification to heptad repeat 1 of gp41 improves yield and/or quality of soluble pre-fusion HIV-1 envelope glycoprotein trimers. Journal of virology. 2025 Academic Article GET IT
Precise targeting of HIV broadly neutralizing antibody precursors in humans. Science (New York, N.Y.). 2025 Academic Article GET IT
Times cited: 5
The HIV-1 envelope glycoprotein: structure, function and interactions with neutralizing antibodies. Nature reviews. Microbiology. 2025 Review GET IT
Fusion of Complement Fragment C3d Enhances Germinal Center Responses to HIV-1 Envelope Glycoproteins. 2025 GET IT
Germline-targeting Strategies to Induce bNAbs against HIV-1. Current HIV research. 2025 Academic Article GET IT
Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response. Nature communications. 2025 Academic Article GET IT
Germline-targeting HIV Envelope SOSIP immunization more frequently elicits broadly-neutralizing antibody precursor responses in infant compared to juvenile rhesus macaques. 2025 GET IT
In danger: HIV vaccine research and development in Europe. PLOS global public health. 2025 Academic Article GET IT
Times cited: 1
Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein. Proceedings of the National Academy of Sciences of the United States of America. 2025 Academic Article GET IT
RBD-depleted SARS-CoV-2 spike generates protective immunity in cynomolgus macaques. NPJ vaccines. 2025 Academic Article GET IT
Times cited: 1
Whole-body visualization of SARS-CoV-2 biodistribution in vivo by immunoPET imaging in non-human primates. Nature communications. 2025 Academic Article GET IT
Times cited: 3
The Design and Immunogenicity of an HIV-1 Clade C Pediatric Envelope Glycoprotein Stabilized by Multiple Platforms. Vaccines. 2025 Academic Article GET IT
Times cited: 1
Anti-immune complex antibodies are elicited during repeated immunization with HIV Env immunogens. Science immunology. 2025 Academic Article GET IT
Times cited: 1
Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadth. EBioMedicine. 2025 Academic Article GET IT
Polyfunctionality and breadth of HIV-1 antibodies are associated with delayed disease progression. PLoS pathogens. 2024 Academic Article GET IT
Times cited: 3
Plant-produced SARS-CoV-2 antibody engineered towards enhanced potency and in vivo efficacy. Plant biotechnology journal. 2024 Academic Article GET IT
Times cited: 2
Mosaic and mixed HIV-1 glycoprotein nanoparticles elicit antibody responses to broadly neutralizing epitopes. PLoS pathogens. 2024 Academic Article GET IT
Times cited: 3
Design and immunogenicity of an HIV-1 clade C pediatric envelope glycoprotein stabilized by multiple platforms. 2024 GET IT
Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses. Cell reports. 2024 Academic Article GET IT
Times cited: 3
Short CDRL1 in intermediate VRC01-like mAbs is not sufficient to overcome key glycan barriers on HIV-1 Env. Journal of virology. 2024 Academic Article GET IT
Times cited: 3
Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies. The Journal of experimental medicine. 2024 Academic Article GET IT
Times cited: 15
Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site. Science immunology. 2024 Academic Article GET IT
Times cited: 19
Immunization with germ line-targeting SOSIP trimers elicits broadly neutralizing antibody precursors in infant macaques. Science immunology. 2024 Academic Article GET IT
Times cited: 12
Broadening sarbecovirus neutralization with bispecific antibodies combining distinct conserved targets on the receptor binding domain. Human vaccines & immunotherapeutics. 2024 Academic Article GET IT
Times cited: 2
Primary SARS-CoV-2 variant of concern infections elicit broad antibody Fc-mediated effector functions and memory B cell responses. PLoS pathogens. 2024 Academic Article GET IT
Times cited: 2
Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing. Communications biology. 2024 Academic Article GET IT
Times cited: 10
Gold Nanoparticle Virus-like Particles Presenting SARS-CoV-2 Spike Protein: Synthesis, Biophysical Properties and Immunogenicity in BALB/c Mice. Vaccines. 2024 Academic Article GET IT
Times cited: 6
Progress on priming HIV-1 immunity. Science (New York, N.Y.). 2024 Comment GET IT
Times cited: 4
HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodies. 2024 GET IT
The molecular immune modulator adenosine deaminase-1 enhances HIV specific humoral and cellular responses to a native-like HIV envelope trimer DNA vaccine. 2024 GET IT
CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits. Nature communications. 2024 Academic Article GET IT
Times cited: 3
A spike virosome vaccine induces pan-sarbecovirus antibody responses in mice. iScience. 2024 Academic Article GET IT
Times cited: 3
Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines. NPJ vaccines. 2024 Academic Article GET IT
Times cited: 7
Anti-Immune Complex Antibodies are Elicited During Repeated Immunization with HIV Env Immunogens. 2024 GET IT
Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses. 2023 GET IT
Germline-targeting SOSIP trimer immunization elicits precursor CD4 binding-site targeting broadly neutralizing antibodies in infant macaques. 2023 GET IT
Correction: HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. 2023 GET IT
Assessing immunogenicity barriers of the HIV-1 envelope trimer. NPJ vaccines. 2023 Academic Article GET IT
Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual. iScience. 2023 Academic Article GET IT
Times cited: 7
A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection. Nature communications. 2023 Academic Article GET IT
Times cited: 28
Virological and immunological correlates of HIV posttreatment control after temporal antiretroviral therapy during acute HIV infection. AIDS (London, England). 2023 Academic Article GET IT
Times cited: 2
Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates. Immunity. 2023 Academic Article GET IT
Times cited: 10
Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens. NPJ vaccines. 2023 Academic Article GET IT
Times cited: 4
Signatures of V_H1-69-derived hepatitis C virus neutralizing antibody precursors defined by binding to envelope glycoproteins. Nature communications. 2023 Academic Article GET IT
Times cited: 9
Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies. Cell reports. 2023 Academic Article GET IT
Times cited: 15
SARS-CoV-2 Spike N-Terminal Domain Engages 9-O-Acetylated α2-8-Linked Sialic Acids. ACS chemical biology. 2023 Academic Article GET IT
Times cited: 19
Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions. Cell reports. Medicine. 2023 Academic Article GET IT
Times cited: 28
Different configurations of SARS-CoV-2 spike protein delivered by integrase-defective lentiviral vectors induce persistent functional immune responses, characterized by distinct immunogenicity profiles. Frontiers in immunology. 2023 Academic Article GET IT
Times cited: 6
Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses. iScience. 2023 Academic Article GET IT
Times cited: 9
Fine-mapping the immunodominant antibody epitopes on consensus sequence-based HIV-1 envelope trimer vaccine candidates. NPJ vaccines. 2022 Academic Article GET IT
Times cited: 11
Induction of cross-neutralizing antibodies by a permuted hepatitis C virus glycoprotein nanoparticle vaccine candidate. Nature communications. 2022 Academic Article GET IT
Times cited: 32
Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses. iScience. 2022 Academic Article GET IT
Times cited: 17
Corrigendum: Anti-HIV-1 nanobody-IgG1 constructs with improved neutralization potency and the ability to mediate Fc effector functions. 2022 GET IT
Times cited: 3
Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer. PLoS pathogens. 2022 Academic Article GET IT
Times cited: 2
Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection. Cell host & microbe. 2022 Academic Article GET IT
Times cited: 32
Structure of the hepatitis C virus E1E2 glycoprotein complex. Science (New York, N.Y.). 2022 Academic Article GET IT
Times cited: 55
Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern. Nature communications. 2022 Academic Article GET IT
Times cited: 14
The SARS-CoV-2 spike N-terminal domain engages 9- O -acetylated α2-8-linked sialic acids. 2022 GET IT
Broad SARS-CoV-2 Neutralization by Monoclonal and Bispecific Antibodies Derived from a Gamma-infected Individual. 2022 GET IT
Comparison of blood and lymph node cells after intramuscular injection with HIV envelope immunogens. Frontiers in immunology. 2022 Academic Article GET IT
Times cited: 11
Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens. Cell reports. Medicine. 2022 Academic Article GET IT
Times cited: 31
Innate cell markers that predict anti-HIV neutralizing antibody titers in vaccinated macaques. Cell reports. Medicine. 2022 Academic Article GET IT
Times cited: 4
Recent infection with HCoV-OC43 may be associated with protection against SARS-CoV-2 infection. iScience. 2022 Academic Article GET IT
Times cited: 19
Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron. Immunity. 2022 Academic Article GET IT
Times cited: 66
A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike. Nature communications. 2022 Academic Article GET IT
Times cited: 41
Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein. Nature communications. 2022 Academic Article GET IT
Times cited: 13
Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection. eLife. 2022 Academic Article GET IT
Times cited: 12
B cells expressing IgM B cell receptors of HIV-1 neutralizing antibodies discriminate antigen affinities by sensing binding association rates. Cell reports. 2022 Academic Article GET IT
Times cited: 8
Conjugation of a Toll-Like Receptor Agonist to Glycans of an HIV Native-Like Envelope Trimer Preserves Neutralization Epitopes. Chembiochem : a European journal of chemical biology. 2022 Academic Article GET IT
Times cited: 5
Structural dynamics reveal isolate-specific differences at neutralization epitopes on HIV Env. iScience. 2022 Academic Article GET IT
Times cited: 14
Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. PLoS medicine. 2022 Academic Article GET IT
Times cited: 78
Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody. Cell reports. Medicine. 2022 Academic Article GET IT
Times cited: 6
Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions. Frontiers in immunology. 2022 Academic Article GET IT
Times cited: 21
Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers. NPJ vaccines. 2022 Academic Article GET IT
Times cited: 3
Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity. The Journal of allergy and clinical immunology. 2022 Academic Article GET IT
Times cited: 64
Computed tomography and [¹⁸F]-FDG PET imaging provide additional readouts for COVID-19 pathogenesis and therapies evaluation in non-human primates. iScience. 2022 Academic Article GET IT
Times cited: 8
Correction: HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry. 2022 GET IT
A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike. Scientific reports. 2022 Academic Article GET IT
Times cited: 12
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients. Blood advances. 2022 Academic Article GET IT
Times cited: 50
Distinct spatial arrangements of ACE2 and TMPRSS2 expression in Syrian hamster lung lobes dictates SARS-CoV-2 infection patterns. PLoS pathogens. 2022 Academic Article GET IT
Times cited: 19
Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller. The Journal of experimental medicine. 2022 Academic Article GET IT
Times cited: 18
High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers. NPJ vaccines. 2022 Academic Article GET IT
Times cited: 18
SARS-CoV-2 infection activates dendritic cells via cytosolic receptors rather than extracellular TLRs. European journal of immunology. 2022 Academic Article GET IT
Times cited: 11
Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination. Diagnostic microbiology and infectious disease. 2022 Academic Article GET IT
Times cited: 4
Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. Cell reports. Medicine. 2022 Academic Article GET IT
Times cited: 8
A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern. Cell reports. Medicine. 2021 Academic Article GET IT
Times cited: 20
A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern. NPJ vaccines. 2021 Academic Article GET IT
Times cited: 14
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination. eLife. 2021 Academic Article GET IT
Times cited: 72
Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses. ACS central science. 2021 Academic Article GET IT
Times cited: 28
Author Correction: Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers. 2021 GET IT
Times cited: 2
Structure-guided envelope trimer design in HIV-1 vaccine development: a narrative review. Journal of the International AIDS Society. 2021 Review GET IT
Times cited: 36
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. Nature communications. 2021 Academic Article GET IT
Times cited: 34
Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses. Journal of virology. 2021 Academic Article GET IT
Times cited: 11
The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization. Journal of virology. 2021 Academic Article GET IT
Times cited: 18
Convergent HIV-1 Evolution upon Targeted Destabilization of the gp120-gp41 Interface. Journal of virology. 2021 Academic Article GET IT
Times cited: 3
Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination. EBioMedicine. 2021 Academic Article GET IT
Times cited: 18
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. Science (New York, N.Y.). 2021 Academic Article GET IT
Times cited: 249
Infection and transmission of SARS-CoV-2 depend on heparan sulfate proteoglycans. The EMBO journal. 2021 Academic Article GET IT
Times cited: 65
Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. Science advances. 2021 Academic Article GET IT
Times cited: 79
Intramolecular quality control: HIV-1 envelope gp160 signal-peptide cleavage as a functional folding checkpoint. Cell reports. 2021 Academic Article GET IT
Times cited: 12
Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. PLoS pathogens. 2021 Academic Article GET IT
Times cited: 18
Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers. NPJ vaccines. 2021 Academic Article GET IT
Times cited: 17
Antibodies from Rabbits Immunized with HIV-1 Clade B SOSIP Trimers Can Neutralize Multiple Clade B Viruses by Destabilizing the Envelope Glycoprotein. Journal of virology. 2021 Academic Article GET IT
Times cited: 7
Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. Nature communications. 2021 Academic Article GET IT
Times cited: 50
Stepwise Conformational Stabilization of a HIV-1 Clade C Consensus Envelope Trimer Immunogen Impacts the Profile of Vaccine-Induced Antibody Responses. Vaccines. 2021 Academic Article GET IT
Times cited: 12
Influenza A Virus Hemagglutinin Trimer, Head and Stem Proteins Identify and Quantify Different Hemagglutinin-Specific B Cell Subsets in Humans. Vaccines. 2021 Academic Article GET IT
Times cited: 13
Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation. Biochemistry. 2021 Academic Article GET IT
Times cited: 47
Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva. Pathogens & immunity. 2021 Academic Article GET IT
Times cited: 87
Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. 2021 GET IT
SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity. Science advances. 2021 Academic Article GET IT
Times cited: 97
SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. Science immunology. 2021 Academic Article GET IT
Times cited: 440
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science (New York, N.Y.). 2021 Academic Article GET IT
Times cited: 271
Human Milk from Previously COVID-19-Infected Mothers: The Effect of Pasteurization on Specific Antibodies and Neutralization Capacity. Nutrients. 2021 Academic Article GET IT
Times cited: 54
High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. Science translational medicine. 2021 Academic Article GET IT
Times cited: 181
A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. Cell host & microbe. 2021 Academic Article GET IT
Times cited: 46
Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike. Cell reports. 2021 Academic Article GET IT
Times cited: 39
Pandemic moves and countermoves: vaccines and viral variants. Lancet (London, England). 2021 Comment GET IT
Times cited: 21
Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva. 2021 GET IT
Virus vaccines: proteins prefer prolines. Cell host & microbe. 2021 Review GET IT
Times cited: 74
Site-specific steric control of SARS-CoV-2 spike glycosylation. 2021 GET IT
The effect of spike mutations on SARS-CoV-2 neutralization. Cell reports. 2021 Academic Article GET IT
Times cited: 161
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. 2021 GET IT
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. 2021 GET IT
A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. 2021 GET IT
Times cited: 113
Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles. NPJ vaccines. 2021 Academic Article GET IT
Times cited: 36
Production of HIV-1 Env-specific antibodies mediating innate immune functions depends on cognate IL-21- secreting CD4+ T cells. Journal of virology. 2021 Academic Article GET IT
Times cited: 5
SARS-CoV-2 recruits a haem metabolite to evade antibody immunity. 2021 GET IT
Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell. 2021 Academic Article GET IT
Times cited: 148
Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. Science (New York, N.Y.). 2020 Academic Article GET IT
Times cited: 310
Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. Immunity. 2020 Academic Article GET IT
Times cited: 150
Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers. Journal of virology. 2020 Academic Article GET IT
Times cited: 15
An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. Cell reports. 2020 Academic Article GET IT
Times cited: 120
Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. PLoS pathogens. 2020 Academic Article GET IT
Times cited: 81
[HIV vaccine: how far along are we?]. Nederlands tijdschrift voor geneeskunde. 2020 Academic Article GET IT
Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. PLoS pathogens. 2020 Academic Article GET IT
Times cited: 58
Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. PLoS pathogens. 2020 Academic Article GET IT
Times cited: 48
Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV. Vaccines. 2020 Academic Article GET IT
Times cited: 11
Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens. eLife. 2020 Academic Article GET IT
Times cited: 128
Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity. 2020 GET IT
An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain. 2020 GET IT
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science (New York, N.Y.). 2020 Academic Article GET IT
Times cited: 877
HIV envelope trimer-elicited autologous neutralizing antibodies bind a region overlapping the N332 glycan supersite. Science advances. 2020 Academic Article GET IT
Times cited: 17
Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and Deletions. Structure (London, England : 1993). 2020 Academic Article GET IT
Times cited: 43
Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?. Cell host & microbe. 2020 Review GET IT
Times cited: 46
Autologous Antibody Responses to an HIV Envelope Glycan Hole Are Not Easily Broadened in Rabbits. Journal of virology. 2020 Academic Article GET IT
Times cited: 29
Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin. Journal of virology. 2020 Academic Article GET IT
Times cited: 28
Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. Cell. 2020 Academic Article GET IT
Times cited: 105
Diverse HIV-1 escape pathways from broadly neutralizing antibody PGDM1400 in humanized mice. mAbs. 2020 Academic Article GET IT
Times cited: 6
The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1. Frontiers in immunology. 2019 Academic Article GET IT
Times cited: 2
Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes. Journal of virology. 2019 Academic Article GET IT
Times cited: 14
Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. Nature communications. 2019 Academic Article GET IT
Times cited: 153
Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics. PLoS pathogens. 2019 Academic Article GET IT
Times cited: 59
Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms. Current opinion in HIV and AIDS. 2019 Review GET IT
Times cited: 27
Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies. Cell host & microbe. 2019 Academic Article GET IT
Times cited: 41
Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. Nature communications. 2019 Academic Article GET IT
Times cited: 116
Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users. Viruses. 2019 Academic Article GET IT
Times cited: 6
Broadly neutralising antibodies in post-treatment control. The lancet. HIV. 2019 Comment GET IT
Times cited: 2
Capturing the inherent structural dynamics of the HIV-1 envelope glycoprotein fusion peptide. Nature communications. 2019 Academic Article GET IT
Times cited: 26
Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine Antigens. Journal of pharmaceutical sciences. 2019 Academic Article GET IT
Times cited: 20
Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers. The Journal of biological chemistry. 2019 Academic Article GET IT
Times cited: 17
Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes. Journal of virology. 2019 Academic Article GET IT
Times cited: 59
HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry. The Journal of biological chemistry. 2019 Academic Article GET IT
Times cited: 32
Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. Immunity. 2018 Academic Article GET IT
Times cited: 55
Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. Immunity. 2018 Academic Article GET IT
Times cited: 135
Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies. Retrovirology. 2018 Review GET IT
Times cited: 33
Short Communication: Protective Efficacy of Broadly Neutralizing Antibody PGDM1400 Against HIV-1 Challenge in Humanized Mice. AIDS research and human retroviruses. 2018 Academic Article GET IT
Times cited: 5
Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen. Cell reports. 2018 Academic Article GET IT
Times cited: 98
Hitting HIV's Harpoon. Immunity. 2018 Comment GET IT
Times cited: 4
Harnessing post-translational modifications for next-generation HIV immunogens. Biochemical Society transactions. 2018 Review GET IT
Times cited: 4
Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. PLoS pathogens. 2018 Academic Article GET IT
Times cited: 22
Variable Domain N-Linked Glycans Acquired During Antigen-Specific Immune Responses Can Contribute to Immunoglobulin G Antibody Stability. Frontiers in immunology. 2018 Academic Article GET IT
Times cited: 49
Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination. Journal of virology. 2018 Academic Article GET IT
Times cited: 69
Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. PLoS pathogens. 2018 Academic Article GET IT
Times cited: 93
Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages. Journal of proteome research. 2018 Academic Article GET IT
Times cited: 20
cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate. Biotechnology and bioengineering. 2017 Academic Article GET IT
Times cited: 65
Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers. The Journal of biological chemistry. 2017 Academic Article GET IT
Times cited: 32
High-Throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers. Journal of virology. 2017 Academic Article GET IT
Times cited: 24
The microanatomic segregation of selection by apoptosis in the germinal center. Science (New York, N.Y.). 2017 Academic Article GET IT
Times cited: 202
A single mutation in Taiwanese H6N1 influenza hemagglutinin switches binding to human-type receptors. EMBO molecular medicine. 2017 Academic Article GET IT
Times cited: 42
Opposites attract in bispecific antibody engineering. The Journal of biological chemistry. 2017 Comment GET IT
Times cited: 3
Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. The Journal of experimental medicine. 2017 Academic Article GET IT
Times cited: 154
Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization. Cell reports. 2017 Academic Article GET IT
Times cited: 135
HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. PloS one. 2017 Academic Article GET IT
Times cited: 14
Structure and topology around the cleavage site regulate post-translational cleavage of the HIV-1 gp160 signal peptide. eLife. 2017 Academic Article GET IT
Times cited: 46
Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. Journal of virology. 2017 Academic Article GET IT
Times cited: 41
Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. Immunity. 2017 Academic Article GET IT
Times cited: 267
Three mutations switch H7N9 influenza to human-type receptor specificity. PLoS pathogens. 2017 Academic Article GET IT
Times cited: 101
Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes. Journal of virology. 2017 Academic Article GET IT
Times cited: 28
Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. Current opinion in HIV and AIDS. 2017 Review GET IT
Times cited: 32
Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. Cell reports. 2017 Academic Article GET IT
Times cited: 63
Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Science translational medicine. 2017 Academic Article GET IT
Times cited: 126
Native-like Env trimers as a platform for HIV-1 vaccine design. Immunological reviews. 2017 Review GET IT
Times cited: 199
Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer. Cell reports. 2016 Academic Article GET IT
Times cited: 140
HIV's Achilles' Heel. Scientific American. 2016 Academic Article GET IT
Times cited: 6
An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nature microbiology. 2016 Academic Article GET IT
Times cited: 130
HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike. Journal of virology. 2016 Academic Article GET IT
Times cited: 16
Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proceedings of the National Academy of Sciences of the United States of America. 2016 Academic Article GET IT
Times cited: 328
Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. PLoS pathogens. 2016 Academic Article GET IT
Times cited: 123
Probability of N332 glycan occupancy on HIV-1 gp120 modulates sensitivity to broadly neutralizing antibodies. AIDS (London, England). 2016 Academic Article GET IT
Times cited: 1
Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. Cell reports. 2016 Academic Article GET IT
Times cited: 199
HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds. 2016 GET IT
Times cited: 17
Cytokine-Independent Detection of Antigen-Specific Germinal Center T Follicular Helper Cells in Immunized Nonhuman Primates Using a Live Cell Activation-Induced Marker Technique. Journal of immunology (Baltimore, Md. : 1950). 2016 Academic Article GET IT
Times cited: 114
Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. Cell reports. 2016 Academic Article GET IT
Times cited: 220
The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype. AIDS research and human retroviruses. 2016 Academic Article GET IT
Times cited: 11
HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. Trends in immunology. 2016 Review GET IT
Times cited: 85
HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies. Expert review of vaccines. 2016 Review GET IT
Times cited: 33
Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. Cell. 2015 Academic Article GET IT
Times cited: 292
Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans. Immunity. 2015 Academic Article GET IT
Times cited: 170
A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo. PLoS pathogens. 2015 Academic Article GET IT
Times cited: 45
Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens. Journal of virology. 2015 Academic Article GET IT
Times cited: 30
Engineering and Characterization of a Fluorescent Native-Like HIV-1 Envelope Glycoprotein Trimer. Biomolecules. 2015 Academic Article GET IT
Times cited: 10
Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers. Virology. 2015 Academic Article GET IT
Times cited: 41
Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer. Acta crystallographica. Section D, Biological crystallography. 2015 Academic Article GET IT
Times cited: 64
Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity. Retrovirology. 2015 Academic Article GET IT
Times cited: 160
Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. Nature communications. 2015 Academic Article GET IT
Times cited: 80
Reactivation of Neutralized HIV-1 by Dendritic Cells Is Dependent on the Epitope Bound by the Antibody. Journal of immunology (Baltimore, Md. : 1950). 2015 Academic Article GET IT
Times cited: 3
Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens. Proceedings of the National Academy of Sciences of the United States of America. 2015 Academic Article GET IT
Times cited: 110
Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers. Journal of virology. 2015 Academic Article GET IT
Times cited: 74
Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. PLoS pathogens. 2015 Academic Article GET IT
Times cited: 78
Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity. Journal of virology. 2015 Academic Article GET IT
Times cited: 132
Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope Glycoprotein. AIDS research and human retroviruses. 2015 Academic Article GET IT
Times cited: 13
HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science (New York, N.Y.). 2015 Academic Article GET IT
Times cited: 445
Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell. 2015 Academic Article GET IT
Times cited: 224
Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. Cell reports. 2015 Academic Article GET IT
Times cited: 113
Dendritic cell type-specific HIV-1 activation in effector T cells: implications for latent HIV-1 reservoir establishment. AIDS (London, England). 2015 Academic Article GET IT
Times cited: 11
Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. PLoS pathogens. 2015 Academic Article GET IT
Times cited: 86
What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?. Journal of virology. 2015 Academic Article GET IT
Times cited: 24
Gp120/CD4 blocking antibodies are frequently elicited in ART-naïve chronically HIV-1 infected individuals. PloS one. 2015 Academic Article GET IT
Times cited: 5
Colorectal mucus binds DC-SIGN and inhibits HIV-1 trans-infection of CD4+ T-lymphocytes. PloS one. 2015 Academic Article GET IT
Times cited: 12
Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env. Nature communications. 2015 Academic Article GET IT
Times cited: 120
Immunosilencing a highly immunogenic protein trimerization domain. The Journal of biological chemistry. 2015 Academic Article GET IT
Times cited: 60
A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. Journal of virology. 2015 Academic Article GET IT
Times cited: 211
Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proceedings of the National Academy of Sciences of the United States of America. 2014 Academic Article GET IT
Times cited: 298
HIV: A stamp on the envelope. Nature. 2014 Comment GET IT
Times cited: 26
Enhanced immunogenicity of HIV-1 envelope gp140 proteins fused to APRIL. PloS one. 2014 Academic Article GET IT
Times cited: 3
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature. 2014 Academic Article GET IT
Times cited: 379
In vivo protection by broadly neutralizing HIV antibodies. Trends in microbiology. 2014 Academic Article GET IT
Times cited: 34
CD4-induced activation in a soluble HIV-1 Env trimer. Structure (London, England : 1993). 2014 Academic Article GET IT
Times cited: 108
Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology. 2014 Academic Article GET IT
Times cited: 135
Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers. AIDS (London, England). 2014 Letter GET IT
Times cited: 18
Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies. Retrovirology. 2014 Academic Article GET IT
Times cited: 48
Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity. 2014 Academic Article GET IT
Times cited: 319
Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity. 2014 Academic Article GET IT
Times cited: 292
Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens. Journal of immunology (Baltimore, Md. : 1950). 2014 Academic Article GET IT
Times cited: 3
Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development?. Expert review of vaccines. 2014 Editorial Article GET IT
Times cited: 19
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014 Academic Article GET IT
Times cited: 619
ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer. Biochimica et biophysica acta. 2014 Academic Article GET IT
Times cited: 19
HIV takes double hit before entry. BMC biology. 2013 Academic Article GET IT
Times cited: 2
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (New York, N.Y.). 2013 Academic Article GET IT
Times cited: 599
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (New York, N.Y.). 2013 Academic Article GET IT
Times cited: 732
Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proceedings of the National Academy of Sciences of the United States of America. 2013 Academic Article GET IT
Times cited: 159
HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. Retrovirology. 2013 Academic Article GET IT
Times cited: 37
A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS pathogens. 2013 Academic Article GET IT
Times cited: 790
HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans. PloS one. 2013 Academic Article GET IT
Times cited: 7
Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques. Vaccines. 2013 Academic Article GET IT
HIV-1 autologous antibody neutralization associates with mother to child transmission. PloS one. 2013 Academic Article GET IT
Times cited: 14
Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. Journal of virology. 2013 Academic Article GET IT
Times cited: 80
Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. Journal of virology. 2013 Academic Article GET IT
Times cited: 68
Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers. PloS one. 2013 Academic Article GET IT
Times cited: 8
An HIV-1 envelope glycoprotein trimer with an embedded IL-21 domain activates human B cells. PloS one. 2013 Academic Article GET IT
Times cited: 5
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nature structural & molecular biology. 2013 Academic Article GET IT
Times cited: 298
Clinical adjuvant combinations stimulate potent B-cell responses in vitro by activating dermal dendritic cells. PloS one. 2013 Academic Article GET IT
Times cited: 16
Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS pathogens. 2013 Academic Article GET IT
Times cited: 260
Chimeric HIV-1 envelope glycoproteins with potent intrinsic granulocyte-macrophage colony-stimulating factor (GM-CSF) activity. PloS one. 2013 Academic Article GET IT
Times cited: 7
Dendritic cell-induced activation of latent HIV-1 provirus in actively proliferating primary T lymphocytes. PLoS pathogens. 2013 Academic Article GET IT
Times cited: 38
HIV-1 envelope trimer has similar binding characteristics for carbohydrate-binding agents as monomeric gp120. FEBS letters. 2013 Academic Article GET IT
Times cited: 14
Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proceedings of the National Academy of Sciences of the United States of America. 2013 Academic Article GET IT
Times cited: 222
Broadly neutralizing antibodies against HIV-1: templates for a vaccine. Virology. 2013 Review GET IT
Times cited: 83
Potent induction of antibody-secreting B cells by human dermal-derived CD14+ dendritic cells triggered by dual TLR ligation. Journal of immunology (Baltimore, Md. : 1950). 2012 Academic Article GET IT
Times cited: 36
HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells. Journal of immunology (Baltimore, Md. : 1950). 2012 Academic Article GET IT
Times cited: 26
Quantitation of HIV-1 DNA with a sensitive TaqMan assay that has broad subtype specificity. Journal of virological methods. 2012 Academic Article GET IT
Times cited: 11
Optimizing cellular immunity against HIV-1 Gag and preventing suppression by HIV-1 gp120. Expert review of vaccines. 2012 Academic Article GET IT
Times cited: 3
Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin. Journal of virology. 2012 Academic Article GET IT
Times cited: 62
Gene therapy as a vaccine for HIV-1. Expert opinion on biological therapy. 2012 Review GET IT
Times cited: 8
Selective packaging of cellular miRNAs in HIV-1 particles. Virus research. 2012 Academic Article GET IT
Times cited: 17
Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers. The Journal of biological chemistry. 2012 Academic Article GET IT
Times cited: 43
Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance. Virology. 2012 Academic Article GET IT
Times cited: 16
V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc. Virology. 2012 Academic Article GET IT
Times cited: 31
Is there a future for antiviral fusion inhibitors?. Current opinion in virology. 2012 Review GET IT
Times cited: 56
Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. Journal of virology. 2011 Academic Article GET IT
Times cited: 39
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (New York, N.Y.). 2011 Academic Article GET IT
Times cited: 614
HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation. Journal of immunology (Baltimore, Md. : 1950). 2011 Academic Article GET IT
Times cited: 47
Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function. Journal of virology. 2011 Academic Article GET IT
Times cited: 65
Clinical evaluation of a soluble trimeric HIV-1 envelope glycoprotein vaccine. Expert review of vaccines. 2011 Comment GET IT
Times cited: 9
Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice. AIDS research and human retroviruses. 2011 Academic Article GET IT
Times cited: 30
Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proceedings of the National Academy of Sciences of the United States of America. 2011 Academic Article GET IT
Times cited: 140
A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells. Retrovirology. 2011 Academic Article GET IT
Times cited: 28
Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. Journal of virology. 2011 Academic Article GET IT
Times cited: 54
How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?. AIDS research and human retroviruses. 2011 Review GET IT
Times cited: 62
A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses. The Journal of biological chemistry. 2011 Academic Article GET IT
Times cited: 15
Molecular strategies to design an escape-proof antiviral therapy. Antiviral research. 2011 Review GET IT
Times cited: 32
Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution. The Journal of biological chemistry. 2010 Academic Article GET IT
Times cited: 22
IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS research and human retroviruses. 2010 Academic Article GET IT
Times cited: 99
Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. Journal of virology. 2010 Academic Article GET IT
Times cited: 121
Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology. 2010 Academic Article GET IT
Times cited: 64
Inhibition of HIV-1 by fusion inhibitors. Current pharmaceutical design. 2010 Review GET IT
Times cited: 74
Sealing the envelope - the HIV-1 envelope glycoproteins as targets for therapeutics and vaccines. Current pharmaceutical design. 2010 Editorial Article GET IT
The future of influenza vaccines. BMJ (Clinical research ed.). 2009 Editorial Article GET IT
Times cited: 6
Mucin 6 in seminal plasma binds DC-SIGN and potently blocks dendritic cell mediated transfer of HIV-1 to CD4(+) T-lymphocytes. Virology. 2009 Academic Article GET IT
Times cited: 51
Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS pathogens. 2009 Academic Article GET IT
Times cited: 62
HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nature immunology. 2009 Academic Article GET IT
Times cited: 256
Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. The Journal of biological chemistry. 2009 Academic Article GET IT
Times cited: 69
Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. Virology. 2009 Academic Article GET IT
Times cited: 47
Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. Journal of virology. 2008 Academic Article GET IT
Times cited: 38
Evolution rescues folding of human immunodeficiency virus-1 envelope glycoprotein GP120 lacking a conserved disulfide bond. Molecular biology of the cell. 2008 Academic Article GET IT
Times cited: 9
Only five of 10 strictly conserved disulfide bonds are essential for folding and eight for function of the HIV-1 envelope glycoprotein. Molecular biology of the cell. 2008 Academic Article GET IT
Times cited: 40
Selection of T1249-resistant human immunodeficiency virus type 1 variants. Journal of virology. 2008 Academic Article GET IT
Times cited: 72
The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. Retrovirology. 2008 Academic Article GET IT
Times cited: 41
HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS pathogens. 2007 Academic Article GET IT
Times cited: 132
Antibodies to HIV-1: aiming at the right target. Trends in microbiology. 2007 Academic Article GET IT
Times cited: 10
Histatin 5-derived peptide with improved fungicidal properties enhances human immunodeficiency virus type 1 replication by promoting viral entry. Journal of virology. 2006 Academic Article GET IT
Times cited: 30
Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. Journal of virology. 2005 Academic Article GET IT
Times cited: 111
Protein promiscuity: drug resistance and native functions--HIV-1 case. Journal of biomolecular structure & dynamics. 2005 Academic Article GET IT
Times cited: 16
Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN--gp120 interaction. Journal of virology. 2005 Academic Article GET IT
Times cited: 129
Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. Journal of virology. 2004 Academic Article GET IT
Times cited: 132
Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure. AIDS research and human retroviruses. 2004 Academic Article GET IT
Times cited: 20
Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41. Retrovirology. 2004 Academic Article GET IT
Times cited: 33
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. Journal of virology. 2002 Academic Article GET IT
Times cited: 406
Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. Journal of virology. 2002 Academic Article GET IT
Times cited: 123
Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. Journal of virology. 2002 Academic Article GET IT
Times cited: 148
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. Journal of virology. 2002 Academic Article GET IT
Times cited: 523
Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. Journal of virology. 2002 Academic Article GET IT
Times cited: 127
Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits. Journal of virology. 2000 Academic Article GET IT
Times cited: 101
A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. Journal of virology. 2000 Academic Article GET IT
Times cited: 489

more ...

less ...

Background

education and training

Ph.D., University of Amsterdam (Netherlands) 2004
M.Sc., University of Amsterdam (Netherlands) 1999

Contact

full name

Rogier W Sanders

primary email

rws2002@med.cornell.edu

VIVO Weill Cornell Medical College

Rogier W Sanders Adjunct Associate Professor of Research in Microbiology and Immunology

Publications

selected publications

Background

education and training

Contact

full name

primary email